Annovis Bio, Inc. will begin an Open-Label Extension (OLE) study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in Parkinson’s disease patients. The study aims to enroll 500 patients who will be treated with buntanetap for 36 months. Enrollment will include former participants of buntanetap clinical studies and patients receiving deep brain stimulation treatment. The study will assess treatment persistence and address an underserved population. It represents a crucial step towards a future New Drug Application (NDA) submission, helping Annovis meet FDA requirements. For more information, visit the company’s website.

Read more at GlobeNewswire: Annovis Announces Open-Label Extension Study for